Papilocare

Product Description

Gel for the prevention and adjuvant treatment of HPV-induced lesions:

· Medical Device Class IIa. Patented Vaginal Gel.

· Innovative & Unique (1st Treatment for HPV-dependent cervical low grade lesions)

· Target Patients: HPV+ and HPV+ with lesions (ASCUS or LSIL)

· Indicated as a secondary prevention and treatment.

· Encapsulating system: Niosomes & Phytomsomes

· Effect on 3 modifiable factors. Unique combination for a synergistic action (1+2: Allows to modify 3)

Reepithelization of the vaginal transformation zone

Rebalance the vaginal microbiota

Counteracts the non-inflammatory microenvironment

· Primary end-point: 88% HR HPV+ vs 56% CG at 6 months in clearance of cervical lesions.

· Secondary end-point: 63% HR HPV+ vs 40% CG at 6 months in HPV clearance.

· Significant reduction of Stress and high level of adherence

· Journal of Lower Genital Tract Disease: March 2021 Study Paloma Publication (Phase IIb)

Visit our Website:
https://www.papilocare.com/